Case Report

Transcatheter Mitral Valve Repair in a Patient with Osteogenesis Imperfecta: A Case Report and Literature Review

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Abstract

With the emergence of less invasive transcatheter valvular therapies, there remains a limited understanding of the feasibility and durability of these approaches in patients with osteogenesis imperfecta and whether they can offer a suitable alternative to conventional surgery. In this context, and with a focus on mitral repair, we report on a case of mitral transcatheter edge-to-edge repair in a patient with osteogenesis imperfecta and conduct a comprehensive review of the characteristics and outcomes of reported osteogenesis imperfecta cases undergoing surgical or transcatheter mitral repair. Given the high burden of complications of surgery in this population, transcatheter mitral repair could potentially serve as a suitable alternative to conventional surgery in this challenging population.

Disclosure:The authors have no conflicts of interest to declare.

Received:

Accepted:

Published online:

Informed Consent:

The patient has given written informed consent.

Acknowledgements:MH and YM contributed equally and are co-first authors.

Correspondence Details:Yosef Manla, Department of Cardiology, Heart, Vascular and Thoracic Institute, Cleveland Clinic Abu Dhabi, Al-Maryah Island, Abu Dhabi, United Arab Emirates. E: Yosef.manla1@gmail.com

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Osteogenesis imperfecta (OI) is a hereditary defect in collagen type 1 synthesis. Clinical features of OI include blue sclera, hearing loss and pathologic bone fractures.1,2 While uncommon, those affected by OI are at increased risk of cardiovascular abnormalities, particularly left-sided valvulopathies.1,3 In the largest cohort study of OI patients to date, the prevalence of mitral regurgitation (MR) and aortic regurgitation (AR) was estimated at 1.6% and 0.9%, respectively, with an increased cumulative incidence after reaching 50–60 years of age.3 However, surgical intervention on these lesions is hindered by considerable mortality burden and the susceptibility to bleeding and dehiscence of implanted valves.1,2,4 With the emergence of less invasive transcatheter valvular therapies, there remains a limited understanding of the feasibility and durability of these approaches in those with OI and whether they can offer a suitable alternative to conventional surgery. In this context, and with a focus on mitral repair, we report the third case in the literature of mitral transcatheter edge-to-edge repair (MTEER) in a patient with OI and conduct a comprehensive review of the characteristics and outcomes of reported OI cases who underwent surgical or transcatheter mitral repair.

Published cases with OI and MR undergoing surgical or transcatheter mitral valve repair up to date (July 2023) were identified by searching PubMed and Google Scholar using the search terms “osteogenesis imperfecta,” “MitraClip”, “Mitral valve repair”, “mitral repair” and “transcatheter mitral repair”. Two cases of MTEER and 16 cases of surgical mitral valve repair (SMVr) were identified and included in this report (Table 1).4–19

Table 1: Characteristics and Outcomes of Published Cases

Article image

Case Presentation:

A 33-year-old woman with a history of OI presented to an external medical facility with progressive dyspnoea on minimal exertion and was diagnosed with acute heart failure in the setting of severe MR, she was given diuresis treatment and discharged home. Two months later, she presented again with dyspnoea, which prompted a transfer to the authors’ centre for specialist care. On examination, the patient had ascites, blue sclera, scoliosis, hearing impairment and short stature. Cardiac examination was significant for a grade 5–6 pan-systolic murmur and inspiratory crackles in the lower lung fields. A transoesophageal echocardiogram showed biventricular and biatrial dilatation with preserved left ventricular systolic function, severe eccentric posteriorly directed MR (+4, regurgitant orifice area = 1.8 cm2) caused by mitral valve prolapse of the anterior leaflet at A2 scallop (Figure 1A–C and Supplementary Videos 1 and 2), mild AR, moderate tricuspid valve regurgitation and a right ventricular systolic pressure of 89 mmHg.

Due to the substantial risks associated with open surgery, a percutaneous mitral valve repair was planned. The procedure was conducted via right femoral venous access under fluoroscopic guidance. The MitraClip (Abbott) steerable guide was advanced through the interatrial septum into the left atrium and positioned perpendicular to the coaptation line. After echocardiographic confirmation that the MitraClip was at the site of the prolapsed A2 scallop, the delivery catheter was advanced into the left ventricle. The delivery catheter was slightly retracted to engage the MitraClip device with the targeted scallop and an XTW sized clip was inserted at the A2-P2 segment. Transoesophageal echocardiography confirmed the reduction of MR from severe to trivial with a mean gradient of 4 mmHg (Figure 1C–E; Supplementary Videos 3 and 4). The patient’s post-procedural recovery was uneventful and she was discharged home on the fourth post-procedural day on guideline-directed medical therapy (GDMT). At her 1-month follow-up appointment, the patient was haemodynamically stable and GDMT was well-tolerated. No adverse events or hospitalisations for heart failure were reported at 3-month follow-up.

Figure 1: Pre-MitraClip and Post-MitraClip Echocardiographic Findings

Article image

Discussion

Osteogenesis imperfecta is an autosomally inherited defect in the synthesis of type I collagen, primarily caused by pathogenic variants of COL1A1 and COL1A2 genes.20 In 1965, the first report of cardiovascular manifestations in patients with OI was published, reporting two cases of aortic insufficiency and one case with mitral, aortic and pulmonic valve disease.21 Cardiac surgical intervention in patients with OI constitutes a major clinical challenge. The defective interaction between platelets, endothelial cells, capillaries and abnormal collagen contributes to vascular fragility and high vulnerability to valve dehiscence and cardiac rupture.12,22

In a study of 49 OI patients undergoing cardiac surgery, more than 40% of the cases had postoperative bleeding, and almost 1 in 5 died postoperatively.12

Few cases of SMVr in patients with OI have been reported (n=16; Table 1).5–18 Upon review of these cases, the mean age was 49.8 years ±9.6, with a male-to-female predominance (5:1). A minimally invasive surgical approach was used in one case.5 Echocardiographic features and outcomes were detailed in 13 of these cases.5–13,16–18 A concomitant aortic valve pathology was reported in 69.2% (n=9) of the cases. MR resolution was observed in 92.3% (n=12) of cases, although 46.2% (n=6) and 15.4% (n=2) encountered postoperative bleeding and AF, respectively.5–12 On follow-up evaluation, three cases required MV replacement.13,14,16

Data on the feasibility and durability of transcatheter interventions in this population remain scarce, with only two other cases of MTEER reported in OI patients.4,19 Van der Kley et al. detailed a case of a 60-year-old patient undergoing MTEER with an uneventful postoperative course. This was done under fluoroscopy and 3D transoesophageal echocardiography guidance. At the 30-day follow-up, echocardiography revealed a stable position of the MitraClip device with no MR.4 Yap et al. used transthoracic and intracardiac echocardiography to guide their MitraClip procedure. Severe MR was subsequently reduced to ≤2+ postoperatively.19 Improvement in heart failure symptoms was reported at a 30-day follow-up.19 Here, we report the third case of MTEER with an uneventful postprocedural course in a young OI patient with a favourable clinical course. In the above-mentioned three MTEER cases, no complications were reported.

Conclusion

MTEER could potentially serve as a suitable alternative to conventional surgery in OI patients with severe MR. Further studies are warranted to investigate the durability and feasibility of transcatheter valve interventions in this complex patient population.

References

  1. Fraser CD, Ellison TA, Cameron DE, Vricella LA. Connective tissue disorders. In: Mavroudis C, Backer CL. Pediatric Cardiac Surgery 5th ed. 2023; 821–33. Wiley, online. https://onlinelibrary.wiley.com/doi/full/10.1002/9781119282327.ch38
  2. Bonita RE, Cohen IS, Berko BA. Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature. Echocardiography 2010;27:69–73. 
    Crossref | PubMed
  3. Folkestad L, Hald JD, Gram J, et al. Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. Int J Cardiol 2016;225:250–7. 
    Crossref | PubMed
  4. van der Kley F, Delgado V, Marsan NA, Schalij MJ. Transcatheter mitral valve repair in osteogenesis imperfecta associated mitral valve regurgitation. Heart Lung Circ 2014;23:e169–71. 
    Crossref | PubMed
  5. Tagliasacchi I, Martinelli L, Bardaro L, Chierchia S. Minimally invasive mitral valve repair in osteogenesis imperfecta. Interact Cardiovasc Thorac Surg 2017;25:665–6. 
    Crossref | PubMed
  6. Miranda N, Araji OA, Gutierrez-Martin MA, Tellez JC. Mitral valve repair in a patient with mitral regurgitation and osteogenesis imperfecta tarda. Interact Cardiovasc Thorac Surg 2011;13:655–6. 
    Crossref | PubMed
  7. Wakiyama H, Okada Y, Kitamura A, Imai Y. Aortic root replacement with a stentless bioprosthesis in osteogenesis imperfecta. J Heart Valve Dis 2008;17:197–9.
    PubMed
  8. Alfirevic A, Insler S. Deep hypothermic circulatory arrest in a patient with osteogenesis imperfecta. J Cardiothorac Vasc Anesth 2007;21:245–9. 
    Crossref | PubMed
  9. Ohuchi S, Koizumi J, Kin H, et al. Valvular heart surgery in osteogenesis imperfecta. Kyobu Geka 2002;55:1011–3.
    PubMed
  10. Melamed R, Aygen MM, Lowenstein A. Osteogenesis imperfecta with mitral insufficiency due to ballooning of the mitral valve. A case report. Isr J Med Sci 1976;12:1325–8.
    PubMed
  11. Wood SJ, Thomas J, Braimbridge MV. Mitral valve disease and open heart surgery in osteogenesis imperfecta tarda. Br Heart J 1973;35:103–6. 
    Crossref | PubMed
  12. Lamanna A, Fayers T, Clarke S, Parsonage W. Valvular and aortic diseases in osteogenesis imperfecta. Heart Lung Circ 2013;22:801–10. 
    Crossref | PubMed
  13. Vandersteen AM, Lund AM, Ferguson DJP, et al. Four patients with Sillence type I osteogenesis imperfecta and mild bone fragility, complicated by left ventricular cardiac valvular disease and cardiac tissue fragility caused by type I collagen mutations. Am J Med Genet A 2014;164A:386–91. 
    Crossref | PubMed
  14. Santoro G, Scognamiglio G, Palladino MT, et al. ‘Full-metal Jacket’ treatment of multiple paravalvular leaks. J Cardiovasc Med (Hagerstown) 2017;18:455–7. 
    Crossref | PubMed
  15. Najib MQ, Schaff HV, Ganji J, et al. Valvular heart disease in patients with osteogenesis imperfecta. J Card Surg 2013;28:139–43. 
    Crossref | PubMed
  16. Yamaguchi H, Eishi K, Yamachika S, et al. Mitral valve repair in patients with infective endocarditis. Circ J 2006;70:179–83. 
    Crossref | PubMed
  17. Wheatley K, Heng EL, Sheppard M, et al. A case of spontaneous intestinal perforation in osteogenesis imperfecta. J Clin Med Res 2010;2:198–200. 
    Crossref | PubMed
  18. Seto T, Yamamoto T, Shimojima K, Shintaku H. A novel COL1A1 mutation in a family with osteogenesis imperfecta associated with phenotypic variabilities. Hum Genome Var 2017;4:17007. 
    Crossref | PubMed
  19. Yap J, Rogers JH, Aman E, et al. MitraClip implantation guided by volumetric intracardiac echocardiography: technique and feasibility in patients intolerant to transesophageal echocardiography. Cardiovasc Revasc Med 2021;28S:85–8. 
    Crossref | PubMed
  20. Tauer JT, Robinson ME, Rauch F. Osteogenesis imperfecta: new perspectives from clinical and translational research. JBMR Plus 2019;3:e10174. 
    Crossref | PubMed
  21. Criscitiello MG, Ronan JA, Besterman EM, Schoenwetter W. Cardiovascular abnormalities in osteogenesis imperfecta. Circulation 1965;31:255–62. 
    Crossref | PubMed
  22. Minol JP, Zeus T, Blehm A, Veulemans V. TAVI as therapy of choice for aortic valve disease in osteogenesis imperfecta. J Heart Valve Dis 2018;27:104–6.
    PubMed